Navigation Links
U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVie's Humira, as a Result of Its Recent Approval in Ulcerative Colitis
Date:11/14/2013

BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and third-lines, for newly diagnosed ulcerative colitis (UC) patients.

The report entitled Key Findings from Treatment Algorithms in Ulcerative Colitis finds that Janssen's Remicade is the most prescribed biologic for recently treated UC patients, followed by AbbVie's Humira. Patient share for Humira has grown 41 percent over the past year under study, likely due to its FDA approval for use in UC in September 2012. Overall, the use of TNF-alpha inhibitors has increased by 17 percent since 2012.

The findings also reveal that Remicade is more often used as a first-line biologic and therefore had more continuing patients than Humira. However, since Humira is typically used as a later-line biologic, it draws more patients from adding/switching.

"Both Remicade and Humira have very high compliance and persistency rates, which is likely adding to the increased prescriptions," said Decision Resources Analyst Jen Dolga. "However, it is important to note that despite the growth in biologic use, oral aminosalicylates remain the most commonly prescribed drug class for both newly diagnosed and recently treated patients, indicating that a less intimidating side effect profile is still important to gastroenterologists."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, a
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
2. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
6. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
7. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
8. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
9. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
10. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
11. DePuy Settlement Funding And Transvaginal Mesh Capital Increased At Legal-Bay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty ... innovative therapies for the treatment of acute and breakthrough ... chief financial officer  will be participating in three upcoming ... Mizuho Third Annual Healthcare Corporate Access Day ... New York Bank ...
(Date:4/30/2015)... April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the fiscal year ... herein are in Canadian dollars unless otherwise stated. ... significant, with the right strategic partners and additional ...
(Date:4/30/2015)... April 30, 2015  Accuray Incorporated (Nasdaq: ... an agreement with MIM Software Inc. to further ... and CyberKnife ® product portfolios. The new ... technology. This is Accuray,s second collaboration with MIM; ... the first iPad-based treatment plan review capability, PlanTouch™. ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... COLD SPRING HARBOR, N.Y. , May 18 AccuVein ... Medipath Division of Morepen Laboratories to sell the AV300 vein finder in ... signed 30 distributors worldwide. , , ... AccuVein AV300 helps healthcare professionals locate veins for blood draw , ...
... , WINTER PARK, Fla. , May 18 ... cataract surgery and presbyopia, today announced that the company has received ... System for anterior capsulotomy during cataract surgery.   , ... The LensAR Laser System integrates ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3LensAR Laser System(TM) Receives FDA Clearance for Use in Cataract Surgery 2
(Date:5/1/2015)... Providenciales, Turks and Caicos Islands, BWI (PRWEB) May 02, ... has a new website! It is http://www.thevenetiangracebay.com ... resort itself, and it incorporates the stunning white and ... "According to a study of Google, sixty seven percent ... process. The study showed that smartphones were used ...
(Date:5/1/2015)... 2015 Jusuru International has been awarded ... repositioning of its flagship nutritional supplement, Liquid BioCell™ Life, ... new name, new logo, new packaging, new products, and ... designed to identify and promote programs that serve as ... “DSA congratulates Jusuru International for their outstanding accomplishments and ...
(Date:5/1/2015)... 2015 The Workgroup for Electronic ... on the use of health IT to create efficiencies ... resource to the United States Government Accountability Office (GAO) ... cards in Medicare. The report, “ Potential Uses of ... released to the public on Apr. 24, 2015 and ...
(Date:5/1/2015)... 01, 2015 It’s raining bills on Capitol ... proposals to expand federal support for telemedicine. , ... has been working with Congress,” said Jonathan Linkous, CEO of ... the nation is poised to embrace the use of telecommunications ... step in fulfilling ATA’s mission to improve quality, access, equity ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... -- The worldwide incidence of cancer is expected to increase ... than 90 percent in the poorest nations, a new study ... cervical and stomach cancer) appear to be declining in some ... by substantial increases in the types of cancer associated with ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Four University of Houston (UH) students are well on their ... this spring in their work toward new therapies for prostate ... Center for Nuclear Receptors and Cell Signaling (CNRCS), these students ... and expressed, which is vital in developing treatments for cancer. ...
... Philadelphia National data show that currently more than ... obese, and an additional 10 percent are overweight. In ... School of Medicine at the University of Pennsylvania, in ... says that effective strategies to target pregnancy, infancy, and ...
... icon of cleanliness for home and commercial kitchens, restaurants, ... bacteria like other surfaces if not cleaned often. Scientists ... Langmuir , of a practical way to make stainless ... explain that while stainless steel is prized for its ...
... THURSDAY, May 31 (HealthDay News) -- When men are ... their future fertility than women, new Scottish research says. ... information provided to young women diagnosed with cancer and ... fertility expert," study co-author Valerie Peddie, a fertility nurse ...
Cached Medicine News:Health News:Worldwide Cancer Incidence Predicted to Rise 75% by 2030 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Student researchers seek to develop new therapies for cancer 2Health News:Student researchers seek to develop new therapies for cancer 3Health News:Researchers call for obesity prevention efforts to focus on community-wide systems 2Health News:Men and Women With Cancer May Receive Different Fertility Information 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: